Emily K Sims
Indiana University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Emily K Sims as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:47 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05594563 · TArgeting Type 1 Diabetes Using POLyamines (TADPOL)Emily K. Sims · active not recruiting · Type 1 Diabetes · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Indiana Medical Scientist/Engineer Training ProgramT32GM148382 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2025 to 2026 · $942,674 awarded in 2026Same name and institution; not confirmed by an ID
- Implications of Changes in Islet Exosomal Cargo in Type 1 DiabetesR01DK133881 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2022 to 2025 · $653,342 awarded in 2025Same name and institution; not confirmed by an ID
- Beta cell extracellular vesicles in health and diseaseR01DK121929 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2020 to 2024 · $365,064 awarded in 2024Same name and institution; not confirmed by an ID
- Defining the Generation and Cargo of Extracellular Vesicles During the Evolution of Type 1 DiabetesR03DK117253 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2019 to 2020 · $204,816 awarded in 2020Same name and institution; not confirmed by an ID
- Beta cell Derived miR-21 as an Intrinsic Protective Response and Biomarker in Type 1 DiabetesK08DK103983 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2014 to 2018 · $159,338 awarded in 2018Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:47 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.Sci Transl Med · 2021306 citationsRCR 16.9
- Elevations in the Fasting Serum Proinsulin-to-C-Peptide Ratio Precede the Onset of Type 1 Diabetes.Diabetes Care · 2016131 citationsRCR 4.5
- Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes.Cell Rep Med · 202325 citationsRCR 2.5
- The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.Diabetes · 202119 citationsRCR 1.0
- Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab.Diabetologia · 202516 citationsRCR 4.3
- Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals.J Clin Endocrinol Metab · 202411 citationsRCR 1.4
- Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval.Diabetes · 20254 citationsRCR 1.0
- Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 Diabetes.Pediatr Diabetes · 20242 citationsRCR 0.3